PEP-Tz
đź“ť LAB NOTES
PEP-Tz is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist studied for its effects on metabolic signaling, glucose regulation, insulin sensitivity, appetite and satiety pathways, lipid metabolism, and body-weight regulation.
Its combined activity across the GIP and GLP-1 receptor pathways makes PEP-Tz of particular research interest for investigating the biological mechanisms involved in energy balance, nutrient metabolism, glycemic regulation, and metabolic function.
TARGETED RESEARCH USE
GIP and GLP-1 receptor signaling, metabolic regulation, glucose metabolism, insulin sensitivity, appetite and satiety pathways, energy balance, lipid metabolism, body-weight regulation, adipose tissue biology, and obesity-related metabolic research.
RESEARCH REFERENCES
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide Versus Semaglutide Once Weekly in Patients With Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503–515. — View Study on PubMed
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205–216. — View Study on PubMed
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept. Molecular Metabolism. 2018;18:3–14. — View Full Study on PubMed Central
Rosenstock J, Wysham C, FrĂas JP, et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. The Lancet. 2021;398(10295):143–155. — View Study on PubMed
⚠️ FOR RESEARCH USE ONLY — NOT FOR HUMAN OR ANIMAL USE
This research compound is supplied as a lyophilized powder in a sealed 3 mL vial to support stability and proper laboratory handling. Certificate of Analysis (COA) available for verification. Reconstitution is required prior to research use.